① Due to irregular use of fund-raising, INNOT and its chief financial officer received a "warning letter" from the Beijing Securities Regulatory Bureau, and its enterprise told reporters that it had been reported last year. Prior to this, INNOT had twice been included in the "abnormal business list" by the Beijing Administration for Industry and Commerce ".

② as of January 25, 2024, the number of announcements of punishment of A- share companies reached 279, higher than the total in January last year.

"sci-tech innovation board daily" on January 26 (reporter Zheng bingxun) because of "non-standard management of raised funds" and "non-standard establishment of raised funds system" and other behaviors, in vitro diagnostic enterprise innott (688253.SH) and the company's chief financial officer were issued a "warning letter" by Beijing securities regulatory bureau and recorded in the relevant sanctions of the integrity files of the securities and futures market.

According to the Warning Letter, INNOT was primarily involved in two violations.

first, during the period from September 2022 to March 2023, the cash management balance of innott's special account for raised funds exceeded the authorized amount many times, up to a maximum of 0.292 billion yuan.

Second, INNOT has not set a clear tiered approval authority for the use of proceeds.

The matter first started at the end of August 2022, when INNOTT decided to take out up to $0.47 billion of idle fundraising and up to $0.9 billion of idle self-owned funds for cash management to purchase wealth management products, etc. Prior to this, INNOTT had raised a net capital of 0.8 billion yuan through IPO, of which 0.329 billion yuan was used to "supplement working capital".

however, in the actual financial management process, innault's financial personnel made a mistake and mistakenly used 0.329 billion yuan of raised funds for supplementary flow as their own funds. therefore, the amount used for cash management in the special fund-raising account exceeded the authorized amount of 0.292 billion yuan.

after realizing the problem, innott ratified the over-used 0.292 billion yuan at the end of March 2023 and increased the idle fund-raising of financial management from 0.47 billion yuan to 0.79 billion yuan.

In fact, in addition to the replenishment project, INNOT has four other fundraising projects in progress. The reporter of "Science and Technology Innovation Board Daily" found that announced that it would postpone the completion of one of the fund-raising projects "in vitro diagnostic product research and development and industrialization project (Phase I)" for one year less than half a year after the additional financial fund-raising of INNOT.

The project plans to raise 0.25 billion yuan to expand the production capacity of reagent and instrument products, as well as to support the company's new product development and process technology improvement. The project covers two sub-projects, which are expected to reach production in July 2024 and July 2025 respectively. After extension, they will reach operational status in July 2025 and July 2026 respectively.

The reporter of CRE Daily called the office of the Secretary of the Board of Directors of INNOT and asked whether the project extension was affected by the increase in financial fundraising in addition to the external environment. Enterprise personnel said that there is no relationship between the two, and the company's operations are not affected, cash flow is also safe.

"in fact, we already reported to the exchange in March last year and explained it to the securities regulatory bureau, but with the tightening of supervision, the relevant departments have taken warning administrative supervision measures." The business people responded.

But it is worth mentioning that after inquiring about the national enterprise credit information publicity system, the reporter found that before receiving the "warning letter" from the Beijing Securities Regulatory Bureau, INOTT was also in July and August 2016. Because of "not publicizing the annual report within the prescribed time limit" and "publicizing enterprise information to conceal the true situation and practice fraud", it was twice listed in the "list of business anomalies" by the local industrial and commercial bureau ".

The reporter asked the above-mentioned personnel of INNOT what was the specific reason for the above situation. The other party replied, "The details are not clear, but during the period of seeking listing, the sponsor and audit institutions will conduct a strict investigation on the history of the enterprise. If it was not disclosed at that time, it should not be a major problem."

The reporter of "Science and Technology Innovation Board Daily" also found that, as revealed by the personnel of INNOT, the relevant departments are tightening the supervision of listed companies.

star mining data show that as of January 25, 2024, the number of such announcements in January has reached 279, and 8 enterprises were punished on the 25th alone. **

to the board, for example, on the 25th day in addition to INNOT, there are Eddie Pharmaceuticals (688488.SH), Srui new material (688102.SH), OPT (688686.SH) 3 enterprises were punished.

Among them, Eddie Pharmaceuticals failed to fulfill its review procedures and information disclosure obligations in a timely manner when using idle fund-raising to purchase wealth management products. The company was appointed as the chief financial officer in a timely manner by Jiangsu Securities Regulatory Bureau to take regulatory measures to issue a warning letter, which was recorded in the integrity file of the securities and futures market. Collection

Read 7661

I want to comment

You are welcome to make valuable comments. Advertisements and discordant comments will be deleted and comments will be prohibited from your account.